| 7176311 |
Process for preparing pharmaceutically active compounds |
Mark Edward Bunnage, Keith M. DeVries, Laurence James Harris, Philip Charles Levett, John Paul Mathias +2 more |
2007-02-13 |
| 6916927 |
Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3′,5′-monophosphate phosphodiesterase (cGMP-PDE5) for the treatment of sexual dysfunction |
Mark Edward Bunnage, John Paul Mathias, Anthony Wood |
2005-07-12 |
| 6723719 |
Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3′,5′—monophosphate phosphodiesterase (cGMP PDE5) for the treatment of sexual dysfunction |
Mark Edward Bunnage, John Paul Mathias, Anthony Wood |
2004-04-20 |
| 6677335 |
Pharmaceutically active compounds |
Mark Edward Bunnage, Keith M. DeVries, Laurence James Harris, Philip Charles Levett, John Paul Mathias +2 more |
2004-01-13 |
| 6670366 |
Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction |
Mark Edward Bunnage, John Paul Mathias, Anthony Wood |
2003-12-30 |
| 6458951 |
Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction |
Mark Edward Bunnage, John Paul Mathias, Anthony Wood |
2002-10-01 |
| 6407114 |
Pyrazolopyrimidinone CGMP PDE5 inhibitors for the treatment of sexual dysfunction |
Mark Edward Bunnage, John Paul Mathias, Anthony Wood |
2002-06-18 |
| 6333330 |
Pyrazolopyrimidinone CGMP PDE5 inhibitors for the treatment of sexual dysfunction |
Mark Edward Bunnage, John Paul Mathias, Graham Nigel Maw, David James Rawson, Anthony Wood |
2001-12-25 |
| 6251904 |
Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction |
Mark Edward Bunnage, John Paul Mathias, Anthony Wood |
2001-06-26 |